SciBase Initiates Self-Pay Model in the US to Make Nevisense Test More Accessible to Patients

"We continue to work diligently to expand payer coverage and reimbursement, but we also recognize the urgent need for early detection," said Pia Renaudin, CEO of SciBase. "The Self-Pay Program is a critical step in making Nevisense more widely available to clinicians and patients who value early, accurate melanoma detection at the point of care." " We continue to work diligently to expand payer coverage and reimbursement, but we also recognize the urgent need for early detection," saidPia...

STOCKHOLM, 09/06/2025 (informazione.news - comunicati stampa - salute e benessere)

" ," said Pia Renaudin , CEO of SciBase. " ."

As melanoma rates continue to rise globally, the importance of early diagnosis has never been greater. Nevisense offers a point-of-care solution that enhances clinical decision-making and supports earlier detection - ultimately improving outcomes and reducing the long-term burden on healthcare systems.

With the introduction of the Self-Pay Program, SciBase is reinforcing its commitment to innovation, access, and sustainable healthcare. The initiative enables more patients to benefit from Nevisense while helping clinicians deliver exceptional care through early melanoma detection.

Pia Renaudin , CEO, tel. +46732069802, e-mail: pia.renaudin@scibase.com

 DNB Carnegie Investment Bank AB (publ) Phone: +46 (0)73 856 42 65 E-mail: certifiedadviser@carnegie.se

 

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/scibase/r/scibase-initiates-self-pay-model-in-the-us-to-make-nevisense-test-more-accessible-to-patients,c4160680

The following files are available for download:

 

View original content:https://www.prnewswire.co.uk/news-releases/scibase-initiates-self-pay-model-in-the-us-to-make-nevisense-test-more-accessible-to-patients-302476463.html